Is Semaglutide Safe? What the Research Says About GLP-1 Weight Loss

What Is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a class of medication that mimics a natural gut hormone involved in appetite regulation and blood sugar control. Originally developed for type 2 diabetes under the brand name Ozempic, semaglutide gained FDA approval for chronic weight management as Wegovy in June 2021.

GLP-1 medications have become one of the fastest-growing treatments at med spas and weight loss clinics across the country. Our GLP-1 weight loss guide covers the full treatment landscape, but this article focuses specifically on safety.

FDA Approval History

• December 2017: Ozempic (semaglutide 0.5mg and 1mg) approved for type 2 diabetes
• June 2021: Wegovy (semaglutide 2.4mg) approved for chronic weight management in adults with BMI of 30 or higher (or 27+ with a weight-related condition)
• March 2024: Wegovy approved for cardiovascular risk reduction in adults with obesity and established heart disease

The FDA approval process for Wegovy was supported by one of the largest weight-loss clinical trial programs in pharmaceutical history.

What the Clinical Trials Show

The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program included multiple large-scale, randomized, double-blind, placebo-controlled studies:

STEP 1 (2021)

Nearly 2,000 adults with obesity received weekly semaglutide 2.4mg or placebo for 68 weeks. The semaglutide group lost an average of 14.9% of their body weight compared to 2.4% in the placebo group. Over a third of participants lost 20% or more of their body weight.

STEP 2 (2021)

Focused on adults with type 2 diabetes and obesity, this trial showed an average weight loss of 9.6% — a significant result in a population where weight loss is often more difficult to achieve.

STEP 3 and STEP 4

These trials confirmed that combining semaglutide with intensive behavioral therapy enhanced results, and that stopping the medication led to weight regain in most patients — underscoring that GLP-1 therapy often requires long-term commitment.

SELECT Trial (Cardiovascular Outcomes)

Published in 2023, this landmark trial of over 17,000 participants demonstrated that semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in adults with obesity and established heart disease. This finding led to Wegovy's expanded FDA indication.

Common Side Effects

The most frequently reported side effects are gastrointestinal and tend to be most pronounced during the dose-escalation phase:

• Nausea — affects up to 44% of patients (usually improves after 4-8 weeks)
• Vomiting — reported in approximately 24% of trial participants
• Diarrhea — affects about 30% of patients
• Constipation — reported in approximately 24% of patients
• Abdominal pain — affects about 20% of patients
• Headache and fatigue — common during the first few weeks

Most of these effects are mild to moderate and improve as the body adjusts. Slow dose escalation (starting at 0.25mg weekly and increasing gradually over 16-20 weeks) significantly reduces severity.

Rare but Serious Risks

While uncommon, there are serious risks patients should understand:

• Pancreatitis: Inflammation of the pancreas has been reported. Patients should seek immediate medical attention for severe, persistent abdominal pain
• Gallbladder disease: Rapid weight loss from any cause increases gallstone risk. Semaglutide clinical trials showed higher rates of gallbladder-related events
• Thyroid C-cell tumors: Animal studies (specifically in rodents) showed an increased risk of medullary thyroid carcinoma. This has not been confirmed in humans, but semaglutide carries a boxed warning
• Hypoglycemia: Rare when used alone, but risk increases when combined with insulin or sulfonylureas
• Kidney injury: Severe nausea and vomiting can lead to dehydration, which may affect kidney function

Who Should NOT Take Semaglutide

Semaglutide is contraindicated in patients with:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to semaglutide or any product component
• History of pancreatitis (use with extreme caution)
• Pregnancy or plans to become pregnant (discontinue at least 2 months before conception)

Additionally, patients with a history of eating disorders, severe gastroparesis, or inflammatory bowel disease should discuss risks thoroughly with their physician before starting treatment.

Med Spa vs. Online Telehealth Prescriptions

As GLP-1 medications have surged in popularity, patients have more options than ever for obtaining them — but not all pathways are equally safe:

• Med spas with physician oversight: Offer in-person consultations, regular monitoring of lab work, vital signs, and body composition. This is the gold standard for safety.
• Online telehealth platforms: Some provide adequate care with video consultations and lab requirements. Others are essentially prescription mills with minimal medical oversight. Research the platform carefully.
• Primary care physicians and endocrinologists: Often the most comprehensive approach, especially for patients with diabetes or other medical conditions

Regardless of where you get your prescription, ensure your provider requires baseline blood work, monitors your progress regularly, and has a plan for dose adjustments. Find a supervised GLP-1 weight loss program near you.

Compounded vs. Brand-Name Semaglutide

Due to ongoing shortages, compounding pharmacies have produced their own versions of semaglutide. Important considerations:

• Compounded semaglutide is not FDA-approved and may not have the same purity, potency, or sterility as brand-name products
• The FDA has issued warnings about adverse events associated with compounded semaglutide, including dosing errors
• If using a compounded version, ensure it comes from a 503B-registered outsourcing facility (not a 503A pharmacy), which faces stricter FDA oversight
• Brand-name Wegovy and Ozempic undergo rigorous manufacturing quality controls

The Bottom Line on Safety

Semaglutide is one of the most extensively studied weight-loss medications in history, with a strong safety profile when used appropriately under medical supervision. The benefits — including significant weight loss and cardiovascular risk reduction — are well-documented. However, it is not risk-free and is not appropriate for everyone.

The most important safety factor is proper medical supervision. Whether you choose a local med spa or a telehealth platform, make sure your provider conducts thorough screening, monitors your progress, and is available to manage side effects. Visit our complete GLP-1 weight loss guide to learn more about treatment options.